Abstract | PURPOSE: PATIENTS AND METHODS: Between 2009 and 2014, 562 patients diagnosed with stage III NPC who were treated with a concomitant chemotherapy and intensity-modulated radiotherapy with cumulative cisplatin dose ≥200 mg/m2 were included in this retrospective study. Routine blood and biochemical variables and baseline clinical characteristics (T and N stage, age, sex, and induction chemotherapy) were collected. After inserting 19 hematological parameters into a set, we applied the least absolute shrinkage and selection operator (LASSO) algorithm and restricted cubic splines regression to select valuable parameters for predicting 5-year overall survival (OS). Subsequently, univariate and multivariate survival analyses were used to assess independent indicators of 5-year OS, distant metastasis survival, regional recurrence-free survival (RRFS), and disease-free survival. RESULTS: NAR, MAR, serum lactated dehydrogenase (LDH), and Epstein-Barr virus (EBV)- DNA were selected using LASSO regression, and the optimal cut-off values for NAR, MAR, EBV- DNA, and, LDH were 4.39, 0.3, 1590 copies/mL, and 218.4 IU/L, respectively. In multivariate survival analysis, higher NAR was associated with both poor 5-year OS and RRFS (hazard ratio [HR], 1.88; 95% confidence interval [CI], 1.09-3.25, P = .024; HR, 3.13; 95% CI, 1.42-6.91, P = .005, respectively). CONCLUSION: NAR could be an attractive indicator for evaluating the 5-year OS in patients with stage III NPC, which is closely related to inflammation and circulating lipid metabolism.Level of Evidence: 4.
|
Authors | Jing Li, Yan-Ling Wu, Wen-Fei Li, Jun Ma |
Journal | Laryngoscope investigative otolaryngology
(Laryngoscope Investig Otolaryngol)
Vol. 6
Issue 5
Pg. 1049-1061
(Oct 2021)
ISSN: 2378-8038 [Print] United States |
PMID | 34667849
(Publication Type: Journal Article)
|
Copyright | © 2021 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society. |